Dispensing Study to Assess Visual Performance of Prototype Contact Lenses

June 23, 2015 updated by: Brien Holden Vision
The aim of this study is to assess visual performance of prototype soft contact lens designs compared to commercially available contact lenses over one-week of lens wear.

Study Overview

Status

Completed

Detailed Description

Prospective, participant-masked, multiple arm, crossover dispensing clinical trial where participants will wear prototype (test) and commercial (control) lenses bilaterally. Participants will be stratified based on their refractive error into either presbyopic or non-presbyopic group. Each of the stratified group will have a maximum of 4 parallel arms. Up to 4 test lens designs will be assessed against the control/s in each parallel arm in a randomized cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Study Type

Interventional

Enrollment (Actual)

67

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New South Wales
      • Sydney, New South Wales, Australia, 2052
        • Brien Holden Vision Institue, Clinical Research Trials Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent
  • Be at least 18 years old, male or female
  • Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator
  • Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses
  • Correctable to at least 6/12 (20/40) or better in each eye with contact lenses
  • Be willing to not wear contact lenses for a minimum of 2 days before each stage of the clinical trial (after informed consent)

Exclusion Criteria:

  • Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses
  • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants
  • Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial
  • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used
  • Eye surgery within 12 weeks immediately prior to enrolment for this trial.
  • Previous corneal refractive surgery
  • Contraindications to contact lens wear
  • Known allergy or intolerance to ingredients in any of the clinical trial products

The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Presbyopic group - Low Add

40 years and over Add of less than +1.50D

Control lens : Lotrafilcon B and Senofilcon A

Test lens: Etafilcon A

Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Other Names:
  • Test lens
  • Control lenses
  • Non-presbyopic group
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Iteration X
  • Brand name: Air Optix® Aqua , Acuvue® 1-Day Moist
  • Lens material: Lotrafilcon B , Etafilcon A
  • Brand name: Air Optix® Multifocal, Acuvue® Oasys for Presbyopia
  • Lens material Lotrafilcon B, Senofilcon A
OTHER: Presbyopic group - Med Add

40 years and over Add of +1.50D to +1.75D

Control lens : Lotrafilcon B and Senofilcon A

Test lens: Etafilcon A

Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Other Names:
  • Test lens
  • Control lenses
  • Non-presbyopic group
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Iteration X
  • Brand name: Air Optix® Aqua , Acuvue® 1-Day Moist
  • Lens material: Lotrafilcon B , Etafilcon A
  • Brand name: Air Optix® Multifocal, Acuvue® Oasys for Presbyopia
  • Lens material Lotrafilcon B, Senofilcon A
OTHER: Presbyopic group - High Add

40 years and over Add of +2.00D to +2.50D

Control lens : Lotrafilcon B and Senofilcon A

Test lens: Etafilcon A

Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Other Names:
  • Test lens
  • Control lenses
  • Non-presbyopic group
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Iteration X
  • Brand name: Air Optix® Aqua , Acuvue® 1-Day Moist
  • Lens material: Lotrafilcon B , Etafilcon A
  • Brand name: Air Optix® Multifocal, Acuvue® Oasys for Presbyopia
  • Lens material Lotrafilcon B, Senofilcon A
OTHER: Non-presbyopic group

18 to 39 years old No Add

Control lens : Lotrafilcon B and Etafilcon A

Test lens: Etafilcon A

Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Other Names:
  • Test lens
  • Control lenses
  • Non-presbyopic group
  • Lens material: Etafilcon A
  • Presbyopic group
  • Brand name: Iteration X
  • Brand name: Air Optix® Aqua , Acuvue® 1-Day Moist
  • Lens material: Lotrafilcon B , Etafilcon A
  • Brand name: Air Optix® Multifocal, Acuvue® Oasys for Presbyopia
  • Lens material Lotrafilcon B, Senofilcon A

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in visual performance over 1-week lens wear
Time Frame: after about 20 minutes of lens wear and after about 1 week of lens wear
Visual Acuity Visual acuity will be recorded on an interval scale. Data will be summarised as means ± standard deviations. No transformation is likely to be required. Visual acuity will be compared between test and control lens types and time across 1 week. Interactions will be tested and, if present, the significance of lens types will be determined at each time point and over time for each lens type. Visual acuity will be analysed using linear mixed model with subject random intercepts and / or paired t-test.
after about 20 minutes of lens wear and after about 1 week of lens wear

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in subjective response over 1-week of lens wear
Time Frame: After about 40 mins of lens wear and after 2 days, 4 days and 1 week of lens wear
Subjective ratings Questionnaire Subjective ratings will be recorded on a scale of 1 to 10 on steps of 1. Data will be summarised as means ± standard deviations. No transformation is likely to be required. Subjective ratings will be compared between test and control lens types and time across 1 week. Interactions will be tested and, if present, the significance of lens type will be determined at each time point and over time for each lens type. Subjective ratings will be analysed using linear mixed model with subject random intercepts and / or paired t-test.
After about 40 mins of lens wear and after 2 days, 4 days and 1 week of lens wear

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (ACTUAL)

June 1, 2015

Study Completion (ACTUAL)

June 1, 2015

Study Registration Dates

First Submitted

August 7, 2014

First Submitted That Met QC Criteria

August 11, 2014

First Posted (ESTIMATE)

August 12, 2014

Study Record Updates

Last Update Posted (ESTIMATE)

June 25, 2015

Last Update Submitted That Met QC Criteria

June 23, 2015

Last Verified

June 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CRTC2013-02
  • ACTRN12614000011684 (REGISTRY: ANZCTR)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Refractive Error

Clinical Trials on Etafilcon A, Lotrafilcon B , Senofilcon A

Subscribe